Get started
Author

Patrick M. Travis

Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol
2005 · Chandra P. Belani, Hak Choy, et al. · Journal of Clinical Oncology · 423
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
2021 · Jeff P Sharman, Danielle M Brander, et al. · The Lancet Haematology · 51
O-263 Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP) - ACR 427
2003 · Phil Bonomi, Walter Curran, et al. · Lung Cancer · 43
Mode of chemotherapy does not affect complications with an implantable venous access device
1997 · Danielle F. Brown, Michael J. Muirhead, et al. · Cancer · 36
An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development
2011 · Matthew D. Armstrong, Daniel Von Hoff, et al. · Journal of Cancer · 29
PDF
c-myc Transcription is Initiated from Po in 70% of Patients with Multiple Myeloma
1995 · R. G. Hoover, V. Kaushal, et al. · Current topics in microbiology and immunology · 12
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
2020 · Jeff P. Sharman, Danielle M. Brander, et al. · Journal of Clinical Oncology · 9
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.
2017 · Jeff Porter Sharman, Danielle M. Brander, et al. · Journal of Clinical Oncology · 7
Ublituximab and Ibrutinib for Previously Treated Genetically High‐risk Chronic Lymphocytic Leukemia: Results of the Genuine Phase 3 Study
2017 · J.P. Sharman, D.M. Brander, et al. · Hematological Oncology · 6
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma
2025 · Sarah A. Holstein, Shebli Atrash, et al. · Blood · 3
PDF
Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.
2024 · Daneng Li, Anthony F. Shields, et al. · Journal of Clinical Oncology · 3
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic Malignancies
2026 · Benjamin A. Derman, James H. Essell, et al. · JCO Oncology Practice · 1
Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.
2026 · James H. Essell, Benjamin Avi Derman, et al. · Journal of Clinical Oncology
Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment
2025 · Jing-Zhou Hou, Tejvir Singh, et al. · Blood
Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma
2024 · Leena Chhun, Dmytro Assonov, et al. · Blood
Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Shebli Atrash, Sarah A. Holstein, et al. · Blood
PDF
Abstract CT182: Oncolytic virus CF33-hNIS for the treatment of advanced cancer
2024 · Daneng Li, Anthony F. Shields, et al. · Cancer Research
Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma
2023 · Mehdi M. Moezi, Mohamad Kanaan, et al. · Blood
Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.
2023 · Michael A. Kolodziej, Lavi Kwiatkowsky, et al. · Journal of Clinical Oncology
PDF
Works count: 19
Citation count: 623
H-index: 7
I10-index: 6
Year
Topic
Type